• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病淀粉样β 1-42、p-tau 和 t-tau 检测分析。

Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays.

机构信息

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Department of Neurology and Alzheimer Center Amsterdam UMC, Amsterdam, the Netherlands.

出版信息

Alzheimers Dement. 2022 Apr;18(4):635-644. doi: 10.1002/alz.12406. Epub 2021 Jul 26.

DOI:10.1002/alz.12406
PMID:34310035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9249966/
Abstract

INTRODUCTION

We aimed to provide cut points for the automated Elecsys Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers.

METHODS

Cut points for Elecsys amyloid beta 42 (Aβ42), total tau (t-tau), hyperphosphorylated tau (p-tau), and t-tau/Aβ42 and p-tau/Aβ42 ratios were evaluated in Mayo Clinic Study of Aging (n = 804) and Mayo Clinic Alzheimer's Disease Research Center (n = 70) participants.

RESULTS

The t-tau/Aβ42 and p-tau/Aβ42 ratios had a higher percent agreement with normal/abnormal amyloid positron emission tomography (PET) than the individual CSF markers. Reciever Operating Characteristic (ROC)-based cut points were 0.26 (0.24-0.27) for t-tau/Aβ42 and 0.023 (0.020-0.025) for p-tau/Aβ42. Ratio cut points derived from other cohorts performed as well in our cohort as our own did. Individual biomarkers had worse diagnostic properties and more variable results in terms of positive and negative percent agreement (PPA and NPA).

CONCLUSION

CSF t-tau/Aβ42 and p-tau/Aβ42 ratios are very robust indicators of AD. For individual biomarkers, the intended use should determine which cut point is chosen.

摘要

简介

我们旨在为 Elecsys 阿尔茨海默病(AD)脑脊液(CSF)生物标志物的自动分析提供切点。

方法

在 Mayo 诊所衰老研究(n=804)和 Mayo 诊所阿尔茨海默病研究中心(n=70)参与者中,评估 Elecsys 淀粉样蛋白β 42(Aβ42)、总 tau(t-tau)、磷酸化 tau(p-tau)以及 t-tau/Aβ42 和 p-tau/Aβ42 比值的切点。

结果

与单个 CSF 标志物相比,t-tau/Aβ42 和 p-tau/Aβ42 比值与正常/异常淀粉样 PET 的一致性更高。基于接收者操作特征(ROC)的切点为 t-tau/Aβ42 为 0.26(0.24-0.27),p-tau/Aβ42 为 0.023(0.020-0.025)。来自其他队列的比值切点在我们的队列中的表现与我们自己的一样好。个体生物标志物在阳性和阴性百分比一致(PPA 和 NPA)方面具有较差的诊断特性和更多的可变结果。

结论

CSF t-tau/Aβ42 和 p-tau/Aβ42 比值是 AD 的非常可靠指标。对于个体生物标志物,预期用途应确定选择哪个切点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/964b/9542407/b744c78a793b/ALZ-18-635-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/964b/9542407/e5d35b385621/ALZ-18-635-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/964b/9542407/38077b5622a2/ALZ-18-635-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/964b/9542407/8bf1001e4d5d/ALZ-18-635-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/964b/9542407/b744c78a793b/ALZ-18-635-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/964b/9542407/e5d35b385621/ALZ-18-635-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/964b/9542407/38077b5622a2/ALZ-18-635-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/964b/9542407/8bf1001e4d5d/ALZ-18-635-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/964b/9542407/b744c78a793b/ALZ-18-635-g002.jpg

相似文献

1
Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays.阿尔茨海默病淀粉样β 1-42、p-tau 和 t-tau 检测分析。
Alzheimers Dement. 2022 Apr;18(4):635-644. doi: 10.1002/alz.12406. Epub 2021 Jul 26.
2
Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.脑脊液 t-tau/Aβ42 比值与淀粉样蛋白 PET 状态的一致性。
Alzheimers Dement. 2020 Jan;16(1):144-152. doi: 10.1002/alz.12000.
3
Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.记忆门诊队列中脑脊液生物标志物与[11C]PIB PET的一致性
J Alzheimers Dis. 2014;41(3):801-7. doi: 10.3233/JAD-132561.
4
Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.阿尔茨海默病进展中淀粉样蛋白和 tau 生物标志物的相互预测关系:一个经验模型。
J Neurosci. 2019 Sep 11;39(37):7428-7437. doi: 10.1523/JNEUROSCI.1056-19.2019. Epub 2019 Jul 26.
5
Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study.疑似阿尔茨海默病患者的淀粉样蛋白 PET 通常为阴性,但脑脊液磷酸化 tau 蛋白浓度增加,而 Aβ42 浓度极高:一项前瞻性研究。
J Neurol. 2019 Jul;266(7):1685-1692. doi: 10.1007/s00415-019-09315-y. Epub 2019 Apr 8.
6
Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.阿尔茨海默病标准化脑脊液生物标志物在澳大利亚成像、生物标志物和生活方式(AIBL)研究中经PET淀粉样β蛋白特征化的受试者中得到验证。
J Alzheimers Dis. 2015;48(1):175-87. doi: 10.3233/JAD-150247.
7
Cerebral amyloid load determination in a clinical setting: interpretation of amyloid biomarker discordances aided by tau and neurodegeneration measurements.在临床环境中确定脑淀粉样蛋白负荷:通过测量 tau 和神经退行性变来解释淀粉样蛋白生物标志物的不相符。
Neurol Sci. 2022 Apr;43(4):2469-2480. doi: 10.1007/s10072-021-05704-2. Epub 2021 Nov 5.
8
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort.脑脊液生物标志物 Aβ42/40 比值比单独的 Aβ42 更能识别淀粉样 PET 阳性,在异质记忆诊所队列中。
Alzheimers Res Ther. 2022 Apr 26;14(1):60. doi: 10.1186/s13195-022-01003-w.
9
Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.用于阿尔茨海默病常规诊断的 Lumipulse G 脑脊液检测的临床验证。
Alzheimers Res Ther. 2019 Nov 23;11(1):91. doi: 10.1186/s13195-019-0550-8.
10
Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.与临床前阿尔茨海默病核心 CSF 生物标志物相关的纵向结构脑变化:两项独立数据集研究。
Neuroimage Clin. 2018 Apr 16;19:190-201. doi: 10.1016/j.nicl.2018.04.016. eCollection 2018.

引用本文的文献

1
Late-life emergence of neuropsychiatric symptoms and risk of cognitive impairment in cognitively unimpaired individuals.认知功能未受损个体中神经精神症状的晚年出现及认知障碍风险
Alzheimers Dement. 2025 Aug;21(8):e70619. doi: 10.1002/alz.70619.
2
Neutrophils from Alzheimer's Disease mice fail to phagocytose debris and show altered release of immune modulators with age.来自阿尔茨海默病小鼠的中性粒细胞无法吞噬碎片,并且随着年龄增长,其免疫调节剂的释放发生改变。
bioRxiv. 2025 Jul 24:2025.04.21.649766. doi: 10.1101/2025.04.21.649766.
3
Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum.

本文引用的文献

1
CSF biomarkers in Olmsted County: Evidence of 2 subclasses and associations with demographics.奥姆斯特德县脑脊液生物标志物:存在 2 个亚类及与人口统计学指标的关联证据。
Neurology. 2020 Jul 21;95(3):e256-e267. doi: 10.1212/WNL.0000000000009874. Epub 2020 Jun 26.
2
Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging.Elecsys CSF 生物标志物免疫分析与淀粉样蛋白-PET 成像具有一致性。
Alzheimers Res Ther. 2020 Mar 31;12(1):36. doi: 10.1186/s13195-020-00595-5.
3
Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays.
阿尔茨海默病临床谱系中脑脊液淀粉样蛋白和 Tau 生物标志物的变化
JAMA Netw Open. 2025 Jul 1;8(7):e2519919. doi: 10.1001/jamanetworkopen.2025.19919.
4
Capsaicin as a Microbiome Modulator: Metabolic Interactions and Implications for Host Health.辣椒素作为一种微生物群调节剂:代谢相互作用及其对宿主健康的影响
Metabolites. 2025 Jun 5;15(6):372. doi: 10.3390/metabo15060372.
5
Longitudinal Evolution of Posterior Cortical Atrophy: Diagnostic Delays, Overlapping Phenotypes, and Clinical Outcomes.后皮质萎缩的纵向演变:诊断延迟、重叠表型及临床结局
Neurology. 2025 May 13;104(9):e213559. doi: 10.1212/WNL.0000000000213559. Epub 2025 Apr 8.
6
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.阿尔茨海默病淀粉样蛋白PET和脑脊液生物标志物临床应用的考量
Alzheimers Dement. 2025 Mar;21(3):e14528. doi: 10.1002/alz.14528.
7
Ultrasensitive Assays Detect Different Conformations of Plasma β Amyloids.超灵敏检测法可检测血浆β淀粉样蛋白的不同构象。
ACS Omega. 2025 Feb 11;10(7):7256-7263. doi: 10.1021/acsomega.4c10879. eCollection 2025 Feb 25.
8
Exploring cognitive and neuroimaging profiles of dementia subtypes of individuals with dementia in the Democratic Republic of Congo.探索刚果民主共和国痴呆症患者痴呆亚型的认知和神经影像学特征。
Front Aging Neurosci. 2025 Feb 12;17:1552348. doi: 10.3389/fnagi.2025.1552348. eCollection 2025.
9
Focus groups on digital cognitive assessment in the context of Alzheimer's disease.关于阿尔茨海默病背景下数字认知评估的焦点小组讨论。
Digit Health. 2025 Feb 12;11:20552076251318903. doi: 10.1177/20552076251318903. eCollection 2025 Jan-Dec.
10
Blockade of AR improved brain perfusion and cognitive function in a mouse model of Alzheimer's disease.在阿尔茨海默病小鼠模型中,阻断雄激素受体可改善脑灌注和认知功能。
Geroscience. 2025 Jan 22. doi: 10.1007/s11357-025-01526-8.
使用新型 Elecsys Aβ(1-42)、pTau 和 tTau 脑脊液免疫分析物预测临床衰退和向阿尔茨海默病或痴呆的转化。
Sci Rep. 2019 Dec 13;9(1):19024. doi: 10.1038/s41598-019-54204-z.
4
Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment.种族差异在脑脊液淀粉样蛋白和 tau 生物标志物及相关轻度认知障碍的截断值上的表现。
JAMA Netw Open. 2019 Dec 2;2(12):e1917363. doi: 10.1001/jamanetworkopen.2019.17363.
5
PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases.PET 和 CSF 淀粉样蛋白-β状态受患者特征的不同预测:来自不一致病例的信息。
Alzheimers Res Ther. 2019 Dec 7;11(1):100. doi: 10.1186/s13195-019-0561-5.
6
Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease.神经影像学与神经退行性疾病的神经病理模式相关。
Alzheimers Dement. 2019 Jul;15(7):927-939. doi: 10.1016/j.jalz.2019.03.016. Epub 2019 Jun 4.
7
Elecsys Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid.Elecsys 总 tau 和磷酸化 tau(181P)CSF 检测:新型全自动免疫检测方法在定量检测人脑脊液 tau 蛋白中的分析性能。
Clin Biochem. 2019 Oct;72:30-38. doi: 10.1016/j.clinbiochem.2019.05.005. Epub 2019 May 23.
8
Current state of Alzheimer's fluid biomarkers.阿尔茨海默病的体液生物标志物现状。
Acta Neuropathol. 2018 Dec;136(6):821-853. doi: 10.1007/s00401-018-1932-x. Epub 2018 Nov 28.
9
Derivation of cutoffs for the Elecsys amyloid β (1-42) assay in Alzheimer's disease.阿尔茨海默病中Elecsysβ淀粉样蛋白(1-42)检测临界值的推导
Alzheimers Dement (Amst). 2018 Aug 11;10:698-705. doi: 10.1016/j.dadm.2018.07.002. eCollection 2018.
10
Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project.Elecsys免疫分析法对非学术性多中心记忆门诊队列中脑脊液阿尔茨海默病生物标志物的诊断性能:ABIDE项目
Alzheimers Dement (Amst). 2018 Sep 12;10:563-572. doi: 10.1016/j.dadm.2018.08.006. eCollection 2018.